Search

Colestipol

[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia … , colestipol is still generally only employed as an adjunct therapy and the relatively physical nature of its pharmacological activity sometimes limits its usefulness.

Acetyl sulfisoxazole

This process causes an inhibition of bacterial folic acid synthesis and de novo synthesis of purines and pyrimidines, resulting in cell growth arrest and cell death [L2788]. … Sulfisoxazole acetyl is an ester of _sulfisoxazole_, a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial activity.

Tazobactam

It is combined with [Piperacillin] and [Ceftolozane] for the treatment of a variety of bacterial infections. … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.

Polihexanide

Polihexanide, also known as polyhexamethylene biguanide (PHMB), is a broad-spectrum antimicrobial polymer primarily used for topical antisepsis and wound management. … [A1351] It is effective against a wide range of Gram-positive and Gram-negative bacteria.

Odevixibat

[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC

Morphine glucuronide

CoronaVac

The antibodies were found to neutralize 10 representative SARS-CoV-2 strains. As of August 2020, the vaccine is being tested in numerous human clinical trials assessing its safety and immunogenicity. … CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation[A219758].

Lerodalcibep

[L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia … Lerodalcibep is a recombinant fusion protein that binds to and inhibits proprotein convertase subtilisin kexin type 9 (PCSK9).

Ganaxolone

Ganaxolone is the 3β-methylated synthetic analog of [allopregnanolone],[L41130] a metabolite of [progesterone].[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids. … [A245995] Ganaxolone, similar to its endogenous counterparts, is a positive allosteric modulator of GABA_A receptors.

Tislelizumab

[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA.